=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	114.85	450.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-15.00	-15.00

STN INTERNATIONAL LOGOFF AT 09:57:24 ON 10 JAN 2006

Ngrazier 10781442clmland6

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS	12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS	13	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS	14	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	15	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	16	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS	17	DEC 16	MARPATprev will be removed from STN on December 31, 2005
NEWS	18	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	19	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2

NEWS EXPRESS	JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/
NEWS DCOST	SINCE APPROXIMATELY 20:00 COLUMBUS TIME DECEMBER 29, SOME ONLINE COST DISPLAYS HAVE BEEN SHOWING COSTS IN 2006 PRICES FOR STN COLUMBUS FILES. THIS HAS BEEN CORRECTED. PLEASE BE ASSURED THAT YOU WILL BE BILLED ACCORDING TO 2005 PRICES UNTIL JAN 1. PLEASE CONTACT YOUR LOCAL HELP DESK IF YOU HAVE ANY QUESTIONS. WE APOLOGIZE FOR THE ERROR.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Ngrazier 10781442clmland6

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

*IFICDB - The IFI Comprehensive Database from 1950-present
*IFIPAT - The IFI Patent Database from 1950-present
*IFIUDB - The IFI Uniterm Database from 1950-present

* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 09:50:51 ON 10 JAN 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 09:51:55 ON 10 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 JAN 2006 HIGHEST RN 871542-42-6
DICTIONARY FILE UPDATES: 9 JAN 2006 HIGHEST RN 871542-42-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10781442clm1to3.str



chain nodes :
7 8 9 10
ring nodes :
1 2 3 4 5 6 13 14 15 16 17
chain bonds :
2-7 7-8 8-9 8-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-17 14-15 15-16 16-17
exact/norm bonds :
2-7 7-8 8-9 8-10 13-14 13-17 14-15 15-16 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:N,SO2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS
Element Count :
Node 9: Limited
C,C4
S,S1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

Ngrazier 10781442clm1and6



G1 N,SO2

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10781442clm6and8.str



chain nodes :
7 8 9 10 11 18
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17
chain bonds :
2-7 7-8 8-9 8-18 9-10 10-11 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
2-7 7-8 8-9 8-18 9-10 10-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

G1:N,SO2

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS
Element Count :
Node 9: Limited
C,C4
S,S1

Ngrazier 10781442clm1and6

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1 N,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:52:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 43651 TO ITERATE

4.6% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 860549 TO 885491
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:52:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 871498 TO ITERATE

100.0% PROCESSED 871498 ITERATIONS 157 ANSWERS
SEARCH TIME: 00.00.11

L4 157 SEA SSS FUL L1

=> s l2
SAMPLE SEARCH INITIATED 09:53:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 48018 TO ITERATE

4.2% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 947287 TO 973433
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L2

=> s l2 full
FULL SEARCH INITIATED 09:53:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 962273 TO ITERATE

100.0% PROCESSED 962273 ITERATIONS 300 ANSWERS
SEARCH TIME: 00.00.13

L6 300 SEA SSS FUL L2

=> filhcaplus
FILHCAPLUS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> fil hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	334.76	335.18

FILE 'HCAPLUS' ENTERED AT 09:54:09 ON 10 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Jan 2006 VOL 144 ISS 3
FILE LAST UPDATED: 9 Jan 2006 (20060109/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l4
L7 9 L4

=> d ed abs ibib hitstr 1-9

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Mar 2005
GI



I



II

AB The invention relates to a preparation of urotensin II receptor antagonists and CCR-9 antagonists of formula I [wherein: R1, R2, and R3 are independently selected from H, halogen, alkyl, aryl, or CN, etc.; X is CH2, O, or NH, etc.; Y is SO2, C(O), CH2SO2, NHC(O), or NHSO2, etc.; T and W are independently selected from H, (cyclo)alkyl, alkoxy, aryl, or halogen, etc.; R4 is aryl, heterocyclyl, or cycloalkyl]. For instance, thiophenecarboxamide derivative II was prepared via amidation of thiophene-2-carboxylic acid by [2,4,6-trimethyl-3-(pyrrolidin-1-yl)phenyl]amine. The invention compds. were tested for inhibition of human urotensin II-induced Ca2+ mobilization in UTR cells (IC50 > 0.5 μM).

ACCESSION NUMBER: 2005:185392 HCAPLUS
DOCUMENT NUMBER: 142:280229
TITLE: A preparation of urotensin II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, C. Eric; Bui, Huong; Gao, Daxin; Kassir, Jamal; Li, Wen; Wang, Junmei; Biediger, Ronald; Chen, Jie; Market, Robert V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 781,442.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005049286	A1	20050303	US 2004-924180	20040823
US 2004180892	A1	20040916	US 2004-781442	20040218

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-22-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(methoxymethyl)(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-23-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(phenylmethyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-24-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-25-9 HCAPLUS

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PRIORITY APPLN. INFO.: US 2003-448791P P 20030220
US 2004-781442 A2 20040218

OTHER SOURCE(S): MARPAT 142:280229
IT 749266-71-5P 749268-37-9P 749268-38-0P
847414-22-6P 847414-23-7P 847414-24-8P
847414-25-9P 847414-30-6P 847414-31-7P
847414-33-9P 847414-34-0P 847414-35-1P
847414-36-2P 847414-37-3P 847414-38-4P
847414-39-5P 847414-40-8P 847414-41-9P
847414-42-0P 847414-43-1P 847414-44-2P
847414-45-3P 847414-46-4P 847414-47-5P
847414-48-6P 847414-49-7P 847414-50-0P
847414-51-1P 847414-52-2P 847414-53-3P
847414-54-4P 847414-55-5P 847414-56-6P
847414-57-7P 847414-58-8P 847414-59-9P
847414-60-2P 847414-61-3P 847414-62-4P
847414-63-5P 847414-64-6P 847414-82-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urotensin II receptor antagonists and CCR-9 antagonists)
RN 749266-71-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-37-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, 3-[(methylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-30-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-31-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-33-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-methoxyphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-34-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-methylphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-35-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methylphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-39-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-40-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-41-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847414-36-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-37-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-38-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-42-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-43-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-44-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-45-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-46-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-47-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-bromophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-48-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,5-dichlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847414-49-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,5-difluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-50-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-dichlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-51-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-52-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-53-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4,5-trifluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 847414-54-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-(benzoylamino)-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-55-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(4-fluorobenzoyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-56-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-57-7 HCAPLUS
CN 3-Thiophenecarboxamide, 4-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-58-8 HCAPLUS
CN 3-Thiophenecarboxamide, 4,5-dimethyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-59-9 HCAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-60-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,6-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847414-61-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,4-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-62-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-63-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-64-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-82-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[methyl(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



IT **847414-29-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of urotensin II receptor antagonists and CCR-9 antagonists)
RN 847414-29-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-amino-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Sep 2004
GI


I


II


III

AB The title compds. I and II [R1, R2, R3 = H, halo, alkyl, aryl, aralkyl, CN, CF3, etc.; X = N, CH2, or O; Y = SO2, CO, CH2SO2, CH2CO, NHCO, OCO, or NHSO2; R4 = alkyl, aralkyl or (hetero)aryl, R5 = R1, or Z-NR7R8, or R4, R5 taken together with N can form a 5 or 6 membered ring; Z = (CH2)n, where n = 0-6; R6 = (hetero)aryl, Z-NR7R8; R7, R8 = H, alkyl, aryl, aralkyl or together with N form a pyrrolidine, piperazine, piperidine, or morpholine ring; E = substituted amino, O, S, CR13=CR14, or CR13=N, where R13, R14 = alkyl, (hetero)aryl, halo, OH, alkoxy, etc.; D = substituted amino, O, or S; Z = NR15 or CR15R15 where each R15 = H, alkyl, aryl, or heteroaryl; A = (substituted)amino, CO, or SO2; when A =(substituted)amino, B = SO2, CO2, or C16R16, where R16 = H, alkyl, aryl, or heteroaryl; when A = CO or SO2, B = (substituted)amino; R9, R10 = H, alkyl, (hetero)aryl, halo, OH, Alkoxy, or (substituted)amino; R11, R12 = H, alkyl, or (hetero)aryl] were prepared as urotensin-II receptor antagonists and CCR-9 antagonists for the treatment of congestive heart failure, stroke, ischemic heart disease, etc. For example, reaction of 2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylamine (preparation given) with 1-naphthalenesulfonyl chloride yielded compound III. The latter showed an IC50 = 10 μM in the assay of human urotensin-II-induced CA2+ mobilization in UTR cells.

ACCESSION NUMBER: 2004:718308 HCAPLUS
DOCUMENT NUMBER: 141:243188
TITLE: Preparation of phenylenediamine and thiophene carboxylic amide derivatives as urotensin-II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, Eric C.; Bui, Huong; Gao, Daxin; Kassir, Jamal; Li, Wen; Wang, Junmei; Market, Robert V.
PATENT ASSIGNEE(S): Encysive Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 84 pp.

L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073634	A2	20040902	WO 2004-US4645	20040218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2515780	AA	20040902	CA 2004-2515780	20040218
EP 1610753	A2	20060104	EP 2004-712313	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2003-448791P P 20030220
WO 2004-US4645 W 20040218
OTHER SOURCE(S): MARPAT 141:243188
IT **749266-71-5P 749267-36-5P 749267-43-4P 749268-37-9P**, 3-Phenylaminosulfonyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide **749268-38-0P**, 3-Benzenesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of phenylenediamine and thiophene carboxylic amide derivs. as urotensin-II receptor antagonists and CCR-9 antagonists)
RN 749266-71-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749267-36-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-phenyl-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 749267-43-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-bromo-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-37-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 26 Aug 2004
GI


I

AB Title compds. [I; R1, R2 = H, alkyl, alkoxyalkyl, aryloxyalkyl, alkylcarbonyl, alkenylcarbonyl, etc.; R1R2N = atoms to form a 4-10 membered mono-, bi-, or spirocyclic (substituted) ring; R3 = H, alkyl; R4, R5 = H, alkyl, OH, alkoxy, alkylcarbonyloxy, alkylthio; R6-R9 = H, alkyl; R6R7, R8R9 = O; A, B, D, G = N, CR42; AB, DG = CR42; R42 = H, F, Cl, Br, iodo, CF3, NO2, cyano, OCF3, alkoxy, alkylthio, alkenyl, cycloalkyl, cycloalkoxy, cycloalkenyl, alkynyl, CO2H, etc.; R10 = H, alkyl, alkenyl, alkynyl; X = NR52, O, bond, C:C, C.tplbond.C, etc.; R52 = H, alkyl; E = (substituted) C3-14 carbocyclyl, heterocyclyl; K = bond, O, CH2O, S, SO, CO, C:C, C.tplbond.C, etc.; R11 = H, alkyl, alkoxyalkyl, alkenyl, alkynyl, 3-10 membered (substituted) mono-, bi-, tri- or spirocyclic ring; EKR11 = (unsatd.) tricyclic ring; m, n = 0-2], were prepared Thus, N-[1-(4-aminophenyl)pyrrolidin-3-yl]piperidine was treated with carbonyldiimidazole and then with 4-(4-chlorophenyl)piperidine to give 4-(4-chlorophenyl)piperidine-1-carboxylic acid [4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl]amide. The latter at 30 mg/kg orally in female NMRI mice reduced milk consumption by 64%.

ACCESSION NUMBER: 2004:696342 HCAPLUS
DOCUMENT NUMBER: 141:225302
TITLE: Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Stahl, Petra; Gretzke, Dirk
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 390 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072025	A2	20040826	WO 2004-EP1342	20040213
WO 2004072025	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10306250	A1	20040909	DE 2003-10306250	20030214
CA 2516118	AA	20040826	CA 2004-2516118	20040213
EP 1597228	A2	20051123	EP 2004-710808	20040213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2004220191 A1 20041104 US 2004-779853 20040217
PRIORITY APPLN. INFO.: DE 2003-10306250 A 20030214
US 2003-488545P P 20030718
WO 2004-EP1342 W 20040213

OTHER SOURCE(S): MARPAT 141:225302
IT 748167-93-3P 748167-96-6P 748169-24-6P
748172-14-7P 748173-15-1P 748173-46-8P
748173-47-9P 748173-58-2P 748173-65-1P
748174-48-3P 748176-31-0P 748177-24-4P
748178-96-3P 748178-97-4P 748178-98-5P
748181-67-1P 748182-41-4P 748182-42-5P
748182-43-6P 748182-44-7P 748182-45-8P
748182-46-9P 748182-47-0P 748182-48-1P
748182-49-2P 748182-50-5P 748182-51-6P
748182-52-7P 748182-53-8P 748182-54-9P
748182-55-0P 748182-56-1P 748182-57-2P
748182-58-3P 748182-59-4P 748182-60-7P
748182-61-8P 748182-62-9P 748182-63-0P
748182-64-1P 748182-65-2P 748182-66-3P
748182-67-4P 748182-68-5P 748182-69-6P
748182-70-9P 748182-71-0P 748182-72-1P
748182-73-2P 748182-76-5P 748182-81-2P
748182-82-3P 748182-83-4P 748182-84-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-arylheterocycles as MCH antagonists)

RN 748167-93-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(acetylmethylamino)-1-pyrrolidinyl]phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 748167-96-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(acetylmethylamino)-1-pyrrolidinyl]phenyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 748169-24-6 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(2,4-difluorophenyl)-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748173-15-1 HCAPLUS
CN Carbamic acid, methyl[1-[4-[[[4-(2-methyl-5-thiazolyl)-2-thienyl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 1

CRN 748169-23-5
CMF C23 H23 F2 N3 O S

PAGE 1-A



PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 748172-14-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748173-46-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 748173-47-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-3-(1H-pyrrol-1-yl)- (9CI) (CA INDEX NAME)



RN 748173-58-2 HCAPLUS

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 748173-65-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 748174-48-3 HCAPLUS
CN 2-Thiophenecarboxamide, 4-[(4-chlorophenyl)sulfonyl]-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748178-96-3 HCAPLUS
CN Carbamic acid, methyl[1-[4-[[[5-(2-pyridinylethynyl)-2-thienyl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 748178-97-4 HCAPLUS
CN Carbamic acid, [1-[4-[[[5-[(4-fluorophenyl)ethynyl]-2-thienyl]carbonyl]amino]phenyl]-3-pyrrolidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748176-31-0 HCAPLUS
CN 2-Thiophenecarboxamide, 4-(4-chlorophenyl)-N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 748177-24-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748178-98-5 HCAPLUS
CN Carbamic acid, methyl[1-[4-[[[5-(3-pyridinylethynyl)-2-thienyl]carbonyl]amino]phenyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 748181-67-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-(2-methyl-5-thiazolyl)- (9CI) (CA INDEX NAME)



RN 748182-41-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748182-42-5 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(4-methoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-45-8 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(3-ethoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A

RN 748182-43-6 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(3-methoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748182-44-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748182-46-9 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(4-ethoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A

RN 748182-47-0 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(4-cyanophenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 748182-48-1 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(3,4-dimethoxyphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-49-2 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(4-acetylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-50-5 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(2-acetylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 748182-51-6 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(1,3-benzodioxol-5-yl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748182-52-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 748182-53-8 HCAPLUS
CN 2-Thiophenecarboxamide, 5-[4-(ethylthio)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-54-9 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(4-ethylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-55-0 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(3,4-dimethylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-56-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-57-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-58-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[3-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748182-59-4 HCAPLUS
CN Benzoic acid, 4-[5-[[[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]carbonyl]-2-thienyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A

RN 748182-60-7 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(6-methoxy-3-pyridinyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748182-61-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 748182-62-9 HCAPLUS
CN 2-Thiophenecarboxamide, 5-[2-(acetylamino)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748182-63-0 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(3,5-dimethyl-4-isoxazolyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748182-64-1 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(6-fluoro-3-pyridinyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 748182-65-2 HCAPLUS
CN Benzoic acid, 3-[5-[[[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]carbonyl]-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 748182-66-3 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(4-cyclohexylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-67-4 HCAPLUS
CN 2-Thiophenecarboxamide, 5-[4-(acetylamino)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-68-5 HCAPLUS
CN 2-Thiophenecarboxamide, 5-[3-[(dimethylamino)carbonyl]phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-69-6 HCAPLUS
CN 2-Thiophenecarboxamide, 5-[4-[(dimethylamino)carbonyl]phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-70-9 HCAPLUS
CN 2-Thiophenecarboxamide, 5-[4-(dimethylamino)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 748182-71-0 HCAPLUS
CN 2-Thiophenecarboxamide, 5-[3-(acetylamino)phenyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748182-72-1 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(3-acetylphenyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748182-73-2 HCAPLUS
CN [2,2'-Bithiophene]-5-carboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 748182-76-5 HCAPLUS
CN 2-Thiophenecarboxamide, 5-(2-fluoro-3-pyridinyl)-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748182-81-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-[(4-methylphenyl)ethynyl]- (9CI) (CA INDEX NAME)



RN 748182-82-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-(2-pyridinylethynyl)- (9CI) (CA INDEX NAME)



RN 748182-83-4 HCAPLUS
CN 2-Thiophenecarboxamide, 5-[(4-fluorophenyl)ethynyl]-N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 748182-84-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3-(methylamino)-1-pyrrolidinyl]phenyl]-5-(3-pyridinylethynyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 07 May 2004
GI



I



II

AB The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones I and compds. related to pyrrolidones I [R1 = H, alkyl, cycloalkyl; R2 = (un)substituted Ph, CH2Ph, cycloalkyl; R3 = (un)substituted pyridyl, pyrimidinyl, pyrazinyl, Ph]. The invention further relates to methods for identifying and using agents, including small mol. chemical compns. that inhibit HIV replication in a cell, as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS. Preparation of the compds. I is described in 28 synthetic examples. Thus, reacting 4-(3-cyclopentyloxy-4-methoxyphenyl)-pyrrolidin-2-one with 3-bromobenzonitrile in the presence of potassium phosphate and trans-1,2-cyclohexanediamine in DMF/dioxane followed by treating a solution of the resulting benzonitrile with 25% NaOH solution, and then with 35% H2O2 afforded II.

ACCESSION NUMBER: 2004:370899 HCAPLUS
DOCUMENT NUMBER: 140:391194
TITLE: Preparation of pyrrolidones with anti-HIV activity
INVENTOR(S): Wu, Baogen; He, Yun; Nguyen, Truc; Kuhen, Kelli L.; Ellis, David Archer; Jiang, Tao
PATENT ASSIGNEE(S): IRM LLC, Bermuda
SOURCE: PCT Int. Appl., 201 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

L7 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037784	A2	20040506	WO 2003-US33560	20031021
WO 2004037784	A3	20040819		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004157859	A1	20040812	US 2003-690873	20031021

PRIORITY APPLN. INFO.: US 2002-420480P P 20021021
US 2002-422619P P 20021030

OTHER SOURCE(S): MARPAT 140:391194
IT **686712-45-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-phenylpyrrolidin-2-ones with anti-HIV activity)
RN 686712-45-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-[4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-oxo-1-pyrrolidinyl]phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Jul 2001
AB Pharmaceutical and veterinary uses of endothelin antagonists are provided. In particular, methods of treatment of laminitis, such as equine and bovine laminitis, by administration of one or more endothelin antagonists are provided. Methods are also provided for the treatment, prevention, or amelioration of one or more symptoms of menopause; osteoporosis and metabolic bone disorders; climacteric disorders, including hot flushes or flashes, abnormal clotting patterns, urogenital discomfort and increased incidence of cardiovascular disease, and other disorders associated with the reduction in ovarian function in women; pre-eclampsia; and control and management of labor during pregnancy by administration of endothelin antagonists.

ACCESSION NUMBER: 2001:507533 HCAPLUS
DOCUMENT NUMBER: 135:102580
TITLE: Pharmaceutical and veterinary uses of endothelin antagonists for treatment of laminitis and other conditions, and preparation thereof
INVENTOR(S): Brock, Thomas A.; Ward, Patrick R.
PATENT ASSIGNEE(S): Texas Biotechnology Corporation, USA
SOURCE: PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049289	A1	20010712	WO 2000-US35280	20001227
W: AE, AG, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001024567	A5	20010716	AU 2001-24567	20001227

PRIORITY APPLN. INFO.: US 1999-174125P P 19991231
WO 2000-US35280 W 20001227

OTHER SOURCE(S): MARPAT 135:102580
IT **350225-01-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reaction; endothelin antagonists for veterinary or pharmaceutical use in treatment of laminitis and other conditions)
RN 350225-01-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]-, monosodium salt (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Nov 2000
GI



II

AB REZDR3 [I; D,E = Z1NR5C(:X), Z1NR5SO0-2, etc.; R,R3 = (un)substituted heterocyclyl or -acyl; R5 = H, (ar)alkyl, aryl; X = O, S, H2; Z = (un)substituted heterocyclylene or -arylene; Z1 = bond, alkylene, alkylidene, etc.] were prepared as factor Xa, thrombin, and prothrombinase inhibitors. Thus, H2NZCONHC6H4Cl-4 (Z = 4-chloro-1,2-phenylene) (preparation given) was N-acylated by 3-chloro-4-chloromethyl-2-thiophenecarbonyl chloride and the product aminated by 1-methylpiperazine to give title compound II. Data for biol. activity of I were given.

ACCESSION NUMBER: 2000:769086 HCAPLUS
DOCUMENT NUMBER: 133:335159
TITLE: Preparation of N-pyridinyl-2-[(thienylcarbonyl)amino]benzamides and analogs as anticoagulants
INVENTOR(S): Arnaiz, Damian O.; Chou, Yuo-ling; Griedel, Brian D.; Karanjawala, Rushad E.; Kochanny, Monica J.; Lee, Wheeseong; Liang, Amy Mei; Morrissey, Michael M.; Phillips, Gary B.; Sacchi, Karna Lyn; Sakata, Steven T.; Shaw, Kenneth J.; Snider, R. Michael; Wu, Shung C.; Ye, Bin; Zhao, Zuchun
PATENT ASSIGNEE(S): Berlex Laboratories, Inc., USA
SOURCE: U.S., 113 pp., Cont.-in-part of U.S. Ser. No. 994,284, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6140351	A	20001031	US 1998-187459	19981105
CA 2315070	AA	19990701	CA 1998-2315070	19981127
WO 9932477	A1	19990701	WO 1998-EP7650	19981127
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9918759	A1	19990712	AU 1999-18759	19981127
AU 751856	B2	20020829		

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

EP 1040108	A1	20001004	EP 1998-963519	19981127
EP 1040108	B1	20040225		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001526283	T2	20011218	JP 2000-525414	19981127
NZ 503809	A	20020426	NZ 1998-503809	19981127
AT 260103	E	20040315	AT 1998-963519	19981127
RU 2226529	C2	20040410	RU 2000-119756	19981127
PT 1040108	T	20040630	PT 1998-963519	19981127
ES 2215337	T3	20041001	ES 1998-963519	19981127
ZA 9811599	A	19990817	ZA 1998-11599	19981217
NO 2000003111	A	20000818	NO 2000-3111	20000616
US 6380221	B1	20020430	US 2000-631450	20000803
US 6498185	B1	20021224	US 2000-631452	20000803
PRIORITY APPLN. INFO.:			US 1997-994284 B2	19971219
			US 1998-187459 A	19981105
			WO 1998-EP7650 W	19981127

OTHER SOURCE(S): MARPAT 133:335159
IT **229335-18-6P 229337-47-7P 229340-25-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-pyridinyl-2-[(thienylcarbonyl)amino]benzamides and analogs as anticoagulants)
RN 229335-18-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229337-47-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[[(2-hydroxyethyl)methylamino]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 229340-25-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[[(2-hydroxyethyl)methylamino]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229337-47-7
CMF C25 H26 Cl3 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L7 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 05 Oct 1999

AB We have previously disclosed the discovery of 2,4-disubstituted anilinothiophenesulfonamides with potent ETA-selective endothelin receptor antagonism and the subsequent identification of sitaxsentan (TBC11251, 1) as a clin. development compound The orally active 1 has demonstrated efficacy in a phase II clin. trial of congestive heart failure and was active in rat models of myocardial infarction and acute hypoxia-induced pulmonary hypertension. We now report that an addnl. substituent at the 6-position of the anilino ring further increases the potency of this series of compds. It was also found that a wide range of functionalities at the 3-position of the 2,4,6-trisubstituted ring increased ETA selectivity by .apprx.10-fold while maintaining in vitro potency, therefore rendering the compds. amenable to fine-tuning of pharmacol. and toxicol. profiles with enhanced selectivity. The optimal compound in this series was found to be TBC2576, which has .apprx.10-fold higher ETA binding affinity than 1, high ETA/ETB selectivity, and a serum half-life of 7.3 h in rats, as well as in vivo activity.

ACCESSION NUMBER: 1999:628908 HCAPLUS
DOCUMENT NUMBER: 131:346149
TITLE: Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ETA Receptors
AUTHOR(S): Wu, Chengde; Decker, E. Radford; Blok, Natalie; Bui, Huong; Chen, Qi; Raju, B.; Bourgoyne, Andree R.; Knowles, Vippra; Biediger, Ronald J.; Market, Robert V.; Lin, Shuqun; Dupre, Brian; Kogan, Timothy P.; Holland, George W.; Brock, Tommy A.; Dixon, Richard A. F.
CORPORATE SOURCE: Texas Biotechnology Corporation, Houston, TX, 77030, USA
SOURCE: Journal of Medicinal Chemistry (1999), 42(22), 4485-4499
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 205516-14-9P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(synthesis of substituted mesitylcarboxamides with high potency and selectivity for ETA receptors)

RN 205516-14-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 08 Jul 1999

GI



I

AB Title compds. [I; m = 1-3; n = 1-5; B, Q = atoms to form aryl, heterocyclyl rings; D, E = NR5CX; R8NR5CX, NR5SOp, etc.; p = 0-2; X = O, S, H2; R1 = H, alkyl, aryl, aralkyl, halo, haloalkyl, cyano, OR5, CO2R5, NR5R6, CONR5R6 (substituted) heterocyclyl, etc.; R2 = H, alkyl, aryl, aralkyl, halo, haloalkyl, cyano, OR5, CO2R5, CONR5R6, etc.; R3 = (substituted) heterocyclyl, aryl; R4 = H, alkyl, halo, haloalkyl, cyano, NO2, OR5, CO2R5, NR5R6, etc.; R5, R6 = H, alkyl, aryl, aralkyl; R8 = alkylene, alkenylene, alkynylene], were prepared Thus, N-(4-chlorophenyl)-2-[[(4-chloromethyl)-3-chlorothiophen-2-ylcarbonyl]amino]-3-methoxy-5-chlorobenzamide in DMF at 0° was treated with N-methylpiperazine followed by stirring to room temperature to give N-(4-chlorophenyl)-2-[[[4-[(4-methylpiperazin-1-yl)methyl]-3-chlorothiophen-2-yl]carbonyl]amino]-3-methoxy-5-chlorobenzamide. Title compds. routinely inhibited Factor Xa with Ki<3 nM. An aerosol formulation is given.

ACCESSION NUMBER: 1999:421679 HCAPLUS
DOCUMENT NUMBER: 131:87925
TITLE: Preparation of heteroarylcarbonylaminobenzamides and related compounds as anticoagulants.
INVENTOR(S): Arnaiz, Damian O.; Chou, Yuo-Ling; Karanjawala, Rushad E.; Kochanny, Monica J.; Lee, Wheeseong; Liang, Amy Mei; Morrissey, Michael M.; Phillips, Gary B.; Sacchi, Karna Lyn; Sakata, Stephen T.; Shaw, Kenneth J.; Snider, R. Michael; Wu, Shung C.; Ye, Bin; Zhao, Zuchun; Griedel, Brian D.
PATENT ASSIGNEE(S): Schering Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 326 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932477	A1	19990701	WO 1998-EP7650	19981127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6140351	A	20001031	US 1998-187459	19981105
CA 2315070	AA	19990701	CA 1998-2315070	19981127
AU 9918759	A1	19990712	AU 1999-18759	19981127
AU 751856	B2	20020829		

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

EP 1040108	A1	20001004	EP 1998-963519	19981127
EP 1040108	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001526283	T2	20011218	JP 2000-525414	19981127
NZ 503809	A	20020426	NZ 1998-503809	19981127
AT 260103	E	20040315	AT 1998-963519	19981127
RU 2226529	C2	20040410	RU 2000-119756	19981127
NO 2000003111	A	20000818	NO 2000-3111	20000616
PRIORITY APPLN. INFO.:			US 1997-994284 A	19971219
			US 1998-187459 A	19981105
			WO 1998-EP7650 W	19981127

OTHER SOURCE(S): MARPAT 131:87925

IT **229335-18-6P 229337-47-7P 229340-25-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylcarbonylaminobenzamides and related compds. as anticoagulants)

RN 229335-18-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229337-47-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[[(2-hydroxyethyl)methylamino]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 229340-25-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-chloro-N-[4-chloro-2-[[(5-chloro-2-pyridinyl)amino]carbonyl]-6-(1-pyrrolidinyl)phenyl]-4-[[(2-hydroxyethyl)methylamino]methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229337-47-7
CMF C25 H26 Cl3 N5 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L7 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Apr 1998
GI



I

AB R1SO2NHR [I; R = (un)substituted (hetero)aryl; R1 = R2Z2Z1; R2 = (un)substituted Ph; Z1 = thiophene-, furan-, pyrrole-2,3- or -3,2-diyl, etc.; Z2 = COCH2, CONH, CO2, CH:CH, CH2O, etc.] were prepared Thus, 2-methoxycarbonyl-3-thiophenesulfonyl chloride was amidated by 5-amino-4-chloro-3-methylisoxazole and the product converted in 5 steps to title compound II. Data for biol. activity of I were given.

ACCESSION NUMBER: 1998:210751 HCAPLUS
DOCUMENT NUMBER: 128:270601
TITLE: Preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin activity modulators
INVENTOR(S): Wu, Chengde; Raju, Bore Gowda; Kogan, Timothy P.; Blok, Natalie; Woodard, Patricia
PATENT ASSIGNEE(S): Texas Biotechnology Corp., USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9813366	A1	19980402	WO 1997-US17402	19970926
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5962490	A	19991005	US 1996-721183	19960927
CA 2261760	AA	19980402	CA 1997-2261760	19970926
CA 2261760	C	20050329		
AU 9745059	A1	19980417	AU 1997-45059	19970926
AU 736269	B2	20010726		
EP 946552	A1	19991006	EP 1997-943629	19970926
EP 946552	B1	20040707		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9711550	A	20000118	BR 1997-11550	19970926
JP 2000507607	T2	20000620	JP 1998-515979	19970926

L7 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

NZ 334797	A	20010223	NZ 1997-334797		19970926
AT 270669	E	20040715	AT 1997-943629		19970926
NO 9901388	A	19990527	NO 1999-1388		19990322
AU 9935803	A1	19990916	AU 1999-35803		19990622
AU 726595	B2	20001116			

PRIORITY APPLN. INFO.:

US 1996-721183	A 19960927
US 1987-100865	A2 19870925
US 1990-416199	A2 19900515
US 1993-65202	B2 19930520
US 1993-100125	B2 19930730
US 1993-100565	A2 19930730
US 1993-142159	A2 19931021
US 1993-142552	A2 19931021
US 1993-142631	B2 19931021
US 1994-222287	A2 19940405
US 1994-247072	A2 19940520
US 1995-417075	A2 19950404
US 1995-477223	A2 19950606
AU 1996-55367	A 19960404
WO 1996-US4759	A2 19960404
WO 1997-US17402	W 19970926

OTHER SOURCE(S): MARPAT 128:270601

IT 205516-14-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-isoxazolylthiophenesulfonamides and analogs as endothelin activity modulators)

RN 205516-14-9 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Ngrazier 10781442clmland6

=> s l6
L8 11 L6

=> d ed abs ibib hitstr 1-11

L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 09 Dec 2005
GI



I

AB Title compds. I [A = carboxy, carboxy bioisostere; L1 = CH2, OCH2, CH2CH2, etc.; L2 = CONH, NHCO, SO2N, etc.; L3 = (Alk1)m-Zn-(Alk2)p; m, n, p = 0-1; Alk1-2 = alkylene, alkenylene, etc.; Z = O, S, CO, etc.; Ar1 = Ph, 5-6 membered heteroaryl, etc.; Ar2 = 1,3-phenylene, 5-6 membered heteroaryl, etc.; B = ring as defined for Ar2, cycloalkyl, etc.; q = 0-1] are prepared For instance, 5-bromo-2-[[3-((6-chloropyridin-3-yl)sulfamoyl)benzoyl]amino]benzoic acid (II) is prepared from 3-chlorosulfonylbenzoic acid, 5-amino-2-chloropyridine and Me 2-amino-5-bromobenzoate. II has an IC50 between 0.5 and 5 μM for the CRTH2 receptor. I are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity.

ACCESSION NUMBER: 2005:1289855 HCAPLUS
DOCUMENT NUMBER: 144:36197
TITLE: Preparation of substituted benzamides as CRTH2 receptor ligands
INVENTOR(S): Ulven, Trond; Frimurer, Thomas; Rist, Oeystein; Kostenis, Evi; Hoegberg, Thomas
PATENT ASSIGNEE(S): 7TM Pharma A/S, Den.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115374	A1	20051208	WO 2005-EP5883	20050530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2004-12198 A 20040529
GB 2004-14195 A 20040624

L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I

RN 870808-15-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



Br

RN 870808-30-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



Br

L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 870808-10-9P 870808-12-1P 870808-14-3P 870808-15-4P 870808-30-3P, 5-Bromo-2-[[[4-((4-bromophenyl)sulfamoyl)-3-methylthiophene-2-yl]carbonyl]amino]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted benzamides as CRTH2 receptor ligands)
RN 870808-10-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 870808-12-1 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 870808-14-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

L8 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 04 Mar 2005
GI



I



II

AB The invention relates to a preparation of urotensin II receptor antagonists and CCR-9 antagonists of formula I (wherein: R1, R2, and R3 are independently selected from H, halogen, alkyl, aryl, or CN, etc.; X is CH2, O, or NH, etc.; Y is SO2, C(O), CH2SO2, NHC(O), or NHSO2, etc.; T and W are independently selected from H, (cyclo)alkyl, alkoxy, aryl, or halogen, etc.; R4 is aryl, heterocyclyl, or cycloalkyl]. For instance, thiophenecarboxamide derivative II was prepared via amidation of thiophene-2-carboxylic acid by [2,4,6-trimethyl-3-(pyrrolidin-1-yl)phenyl]amine. The invention compds. were tested for inhibition of human urotensin II-induced Ca2+ mobilization in UTR cells (IC50 > 0.5 μM).

ACCESSION NUMBER: 2005:185392 HCAPLUS
DOCUMENT NUMBER: 142:280229
TITLE: A preparation of urotensin II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, C. Eric; Bui, Huong; Gao, Daxin; Kassir, Jamal; Li, Wen; Wang, Junmei; Biediger, Ronald; Chen, Jie; Market, Robert V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 781,442.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005049286	A1	20050303	US 2004-924180	20040823
US 2004180892	A1	20040916	US 2004-781442	20040218
PRIORITY APPLN. INFO.:			US 2003-448791P	P 20030220
			US 2004-781442	A2 20040218

OTHER SOURCE(S): MARPAT 142:280229
IT 749268-37-9P 749268-38-0P 847414-20-4P
847414-21-5P 847414-22-6P 847414-24-8P
847414-26-0P 847414-27-1P 847414-30-6P
847414-31-7P 847414-33-9P 847414-34-0P
847414-35-1P 847414-36-2P 847414-37-3P
847414-38-4P 847414-39-5P 847414-40-8P
847414-41-9P 847414-42-0P 847414-43-1P
847414-44-2P 847414-45-3P 847414-46-4P
847414-47-5P 847414-48-6P 847414-49-7P
847414-50-0P 847414-51-1P 847414-52-2P
847414-53-3P 847414-56-6P 847414-57-7P
847414-58-8P 847414-59-9P 847414-60-2P
847414-61-3P 847414-62-4P 847414-63-5P
847414-64-6P 847414-65-7P 847414-67-9P
847414-70-4P 847414-71-5P 847414-72-6P
847414-73-7P 847414-74-8P 847414-75-9P
847414-77-1P 847414-80-6P 847414-82-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of urotensin II receptor antagonists and CCR-9 antagonists)

RN 749268-37-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-20-4 HCAPLUS

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 847414-21-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 847414-22-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(methoxymethyl)(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-24-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847414-26-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-piperidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-27-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-30-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-31-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-33-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-methoxyphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-34-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-methylphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-35-1 HCAPLUS

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, 3-[[(4-methylphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-36-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-37-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-38-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-39-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-40-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]-N-

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-41-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-42-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-43-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chlorophenyl)sulfonyl]amino]-N-[2,4,6-

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-44-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-45-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3-(trifluoromethoxy)phenyl]sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-46-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-47-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-bromophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 847414-48-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,5-dichlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-49-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,5-difluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-50-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-dichlorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-51-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-52-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 847414-53-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4,5-trifluorophenyl)sulfonyl]amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-56-6 HCAPLUS
CN 3-Thiophenecarboxamide, 2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-57-7 HCAPLUS
CN 3-Thiophenecarboxamide, 4-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-58-8 HCAPLUS
CN 3-Thiophenecarboxamide, 4,5-dimethyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-63-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-64-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-fluorophenyl)amino]sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-65-7 HCAPLUS

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-59-9 HCAPLUS
CN 3-Thiophenecarboxamide, 4-methyl-2-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 847414-60-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,6-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-61-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2,4-dimethyl-3-(1-pyrrolidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-62-4 HCAPLUS

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, N-(3-bromo-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-67-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-70-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopropyl-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-71-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[[(4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-72-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-cyclopentyl-2,4,6-trimethylphenyl)-3-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 847414-73-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethyl[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)



RN 847414-74-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2',6'-dimethyl[1,1'-biphenyl]-3-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-82-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[methyl(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 847414-75-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,2',4,6,6'-pentamethyl[1,1'-biphenyl]-3-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-77-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(diethylamino)-2,4,6-trimethylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 847414-80-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-methoxy-2,4,6-trimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Sep 2004
GI



I



II



III

AB The title compds. I and II [R1, R2, R3 = H, halo, alkyl, aryl, aralkyl, CN, CF3, etc.; X = N, CH2, or O; Y = SO2, CO, CH2SO2, CH2CO, NHCO, OCO, or NHSO2; R4 = alkyl, aralkyl or (hetero)aryl, R5 = R1, or Z-NR7R8, or R4, R5 taken together with N can form a 5 or 6 membered ring; Z = (CH2)n, where n = 0-6; R6 = (hetero)aryl, Z-NR7R8; R7, R8 = H, alkyl, aryl, aralkyl or together with N form a pyrrolidine, piperazine, piperidine, or morpholine ring; E = substituted amino, O, S, CR13=CR14, or CR13=N, where R13, R14 = alkyl, (hetero)aryl, halo, OH, alkoxy, etc.; D = substituted amino, O, or S; Z = NR15 or CR15R15 where each R15 = H, alkyl, aryl, or heteroaryl; A = (substituted)amino, CO, or SO2; when A =(substituted)amino, B = SO2, CO2, or C16R16, where R16 = H, alkyl, aryl, or heteroaryl; when A = CO or SO2, B = (substituted)amino; R9, R10 = H, alkyl, (hetero)aryl, halo, OH, Alkoxy, or (substituted)amino; R11, R12 = H, alkyl, or (hetero)aryl] were prepared as urotensin-II receptor antagonists and CCR-9 antagonists for the treatment of congestive heart failure, stroke, ischemic heart disease, etc. For example, reaction of 2,4,6-trimethyl-3-pyrrolidin-1-yl-phenylamine (preparation given) with 1-naphthalenesulfonyl chloride yielded compound III. The latter showed an IC50 = 10 μM in the assay of human urotensin-II-induced CA2+ mobilization in UTR cells.

ACCESSION NUMBER: 2004:718308 HCAPLUS
DOCUMENT NUMBER: 141:243188
TITLE: Preparation of phenylenediamine and thiophene carboxylic amide derivatives as urotensin-II receptor antagonists and CCR-9 antagonists
INVENTOR(S): Wu, Chengde; Anderson, Eric C.; Bui, Huong; Gao, Dawin; Kassir, Jamal; Li, Wen; Wang, Junmei; Market, Robert V.
PATENT ASSIGNEE(S): Encysive Pharmaceuticals Inc., USA
SOURCE: PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

L8 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073634	A2	20040902	WO 2004-US4645	20040218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2515780	AA	20040902	CA 2004-2515780	20040218
EP 1610753	A2	20060104	EP 2004-712313	20040218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2003-448791P	P 20030220
			WO 2004-US4645	W 20040218

OTHER SOURCE(S): MARPAT 141:243188
IT **749268-37-9P**, 3-Phenylaminosulfonyl-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide **749268-38-0P**, 3-Benzenesulfonylamino-N-(2,4,6-trimethyl-3-pyrrolidin-1-yl-phenyl)-thiophene-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of phenylenediamine and thiophene carboxylic amide derivs. as urotensin-II receptor antagonists and CCR-9 antagonists)
RN 749268-37-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylamino)sulfonyl]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 749268-38-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2,4,6-trimethyl-3-(1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **749268-61-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of phenylenediamine and thiophene carboxylic amide derivs. as urotensin-II receptor antagonists and CCR-9 antagonists)
RN 749268-61-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(methoxymethyl)phenylamino]sulfonyl]-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 05 Mar 2004
GI



AB The title compds. I [X = NH; Y = CO, CS, C=NCN, or X and Y together form an alkene, or cycloalkyl; R1 = (un)substituted-heterocycle, -heterocyclylcarbonyl, NHSO2R3; R2 = electron withdrawing group; R3 = H, (un)substituted alkyl or aryl; R4 = (un)substituted aryl with provisions] and their pharmaceutically acceptable salts are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared by amidation of 3-[(5-chloro-2,3-dihydro-1H-indol-1-yl)sulfonyl]benzoyl chloride (preparation given) with 3-(2-amino-5-bromophenyl)-1,2,4-oxadiazol-5(4H)-one. In assays, the min. inhibitory concentration values (μg/mL) ranged from 0.125 - >128. As antibacterial agents I are useful for sterilization, sanitation, antisepsis, and disinfection.
ACCESSION NUMBER: 2004:182873 HCAPLUS
DOCUMENT NUMBER: 140:235499
TITLE: Preparation of aminoarylbenzoic acid derivatives as antibacterial agents for use as disinfectants and therapeutic agents
INVENTOR(S): Thorarensen, Atli; Ruble, Craig J.; Romero, Donna L.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018461	A2	20040304	WO 2003-US24791	20030820
WO 2004018461	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

L8 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

US 2004142981	A1	20040722	US 2003-645799	20030820
PRIORITY APPLN. INFO.:			US 2002-405614P	P 20020823
			US 2002-413596P	P 20020925
			US 2002-430351P	P 20021202

OTHER SOURCE(S): MARPAT 140:235499
IT **666859-72-9P 666859-73-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)
RN 666859-72-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-bromo-2-cyanophenyl)-4-[[(4-chlorophenyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



RN 666859-73-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-bromo-2-cyanophenyl)-5-[[(4-chlorophenyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



IT **666859-26-3P 666859-28-5P**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of aminoarylbenzoic acid derivs. as antibacterial agents)
RN 666859-26-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-bromo-2-(1H-tetrazol-5-yl)phenyl]-4-[[(4-chlorophenyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 666859-28-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-bromo-2-(1H-tetrazol-5-yl)phenyl]-5-[[(4-chlorophenyl)methylamino]sulfonyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004110802	A1	20040610	US 2003-645802	20030820
PRIORITY APPLN. INFO.:			US 2002-405429P	P 20020823
			US 2002-430592P	P 20021203

OTHER SOURCE(S): MARPAT 140:235498
IT **668975-53-9P 668975-55-1P 668975-56-2P**
668975-57-3P 668975-58-4P 668975-59-5P
668975-86-8P 668975-87-9P 668975-88-0P
668975-89-1P 668975-91-5P 668976-56-5P
668979-22-4P 668979-23-5P 668979-26-8P
668979-27-9P 668979-31-5P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoic acid derivs. as antibacterial agents)
RN 668975-53-9 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[5-[[(4-chlorophenyl)methylamino]sulfonyl]-3-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668975-55-1 HCAPLUS
CN Benzoic acid, 2-[[[5-[(1,3-benzodioxol-5-ylamino)sulfonyl]-3-thienyl]carbonyl]amino]-5-bromo- (9CI) (CA INDEX NAME)



RN 668975-56-2 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[(2,3-dihydro-1,4-benzodioxin-6-

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 05 Mar 2004
GI



AB Title compds. I [X = NH; Y = CO, CS, C(NCN), or X and Y together form an alkene or cycloalkyl; R1 = CO2H; R2 = electron withdrawing group; R4 = (un)substituted heterocycle, provided that the heterocycle is not simultaneously substituted with a sulfonamide and a urea or thiourea] and their pharmaceutically acceptable salts are prepared and disclosed as antibacterial agents. Thus, e.g., II was prepared via conversion of 7-(benzyloxy)-1-methyl-1H-indole-2-carboxylic acid (preparation given) to the acid chloride which is reacted with tert-butyl-2-amino-5-cyanobenzoate then subjected to hydrolysis. For compds. of the invention, the min. inhibitory concentration was determined and found to correspond to a range of 0.0075 - >128 μg/mL. The invention provides antimicrobial agents and methods of using the agents for sterilization, sanitation, antisepsis, disinfection, and treatment of infections in mammals.

ACCESSION NUMBER: 2004:182843 HCAPLUS
DOCUMENT NUMBER: 140:235498
TITLE: Preparation of antibacterial benzoic acid derivatives
INVENTOR(S): Thoracensen, Atli; Ruble, Craig J.; Fisher, Jed F.; Romero, Donna L.; Beauchamp, Thomas J.; Northuis, Jill M.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 500 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018428	A1	20040304	WO 2003-US24796	20030822

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl)amino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668975-57-3 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[(3-chloro-4-fluorophenyl)amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668975-58-4 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[3-methyl-4-[[[4-(4-morpholinyl)phenyl]amino]sulfonyl]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668975-59-5 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[[4-(diethylamino)phenyl]amino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 668975-86-8 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[(3-chloro-4-fluorophenyl)amino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668975-87-9 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[[4-[(diethoxyphosphinyl)methyl]phenyl]amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 668975-91-5 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668976-56-5 HCAPLUS
CN Benzoic acid, 5-cyano-2-[[[4-[[(2,3-dihydro-1H-inden-5-yl)amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668979-22-4 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[(4-chlorophenyl)methylamino]sulfonyl]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 668975-88-0 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[(4-chlorophenyl)amino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668975-89-1 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[5-[[[4-(diethylamino)phenyl]amino]sulfonyl]-3-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 668979-23-5 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[5-[[(4-chlorophenyl)methylamino]sulfonyl]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668979-26-8 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[(4-chlorophenyl)methylamino]sulfonyl]-5-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 668979-27-9 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[4-[[(4-chlorophenyl)methylamino]sulfonyl]-3-methyl-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 668979-31-5 HCAPLUS
CN Benzoic acid, 5-bromo-2-[[[5-methyl-4-[[(2-methyl-5-benzothiazolyl)amino]sulfonyl]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 05 Jan 2003
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Inks containing phthalocyanine compds. I [X1-X4 = SOZ, SO2Z; Z = (un)substituted (cyclo)alkyl, alkenyl, acyl, etc.; Y1-Y4 = H, halo, (cyclo)alkyl, amino, etc.; M = H, metal or oxide, hydroxide, and halide thereof; a1-a4 = 0-4 with the proviso that a1-a4 are not simultaneously 0; b1-b4 = 0-4], II [R1-R8 = H, halo, (cyclo)alkyl, amino, etc.; R11-R18 = H, halo, substituted sulfamoyl], and III [R1-R8 = H, halo, (cyclo)alkyl, amino, etc.; Z1-Z4 = (un)substituted heterocyclic group; l, m, n, p = 1, 2; W1-W4 = necessary atom group for formation of (fused) heterocyclic ring; l, m, n, p = 1, 2], as a primary colorant have excellent color reproducibility and sufficient fatness against light, heat, moisture, and active gases in the surroundings. Thus, the inks can provide colored images and colored materials being excellent in color hue and fastness. They are usable in jet printing ink compns., ink sheets for use in thermal transfer image-forming materials, electrophotog. toners, various coloring compns. for color filters for use in LCD, PDP and CCD, and liquid dyes for various fibers, etc.

ACCESSION NUMBER: 2003:6064 HCAPLUS
DOCUMENT NUMBER: 138:74847
TITLE: Colored image-forming compositions containing phthalocyanine compounds, inks, ink-jet inks, ink-jet recording method and method of improving tolerance to decoloration due to ozone gas
INVENTOR(S): Tateishi, Keiichi; Noro, Masaki; Yabuki, Yoshiharu; Omatsu, Tadashi
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: PCT Int. Appl., 230 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000811	A1	20030103	WO 2002-JP6248	20020621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2003003109	A2	20030108	JP 2001-189982	20010622
JP 2003003099	A2	20030108	JP 2001-190215	20010622
JP 2003003086	A2	20030108	JP 2001-190216	20010622
CA 2422030	AA	20030310	CA 2002-2422030	20020621
EP 1408093	A1	20040414	EP 2002-741247	20020621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003119415	A2	20030423	JP 2002-183156	20020624
US 2004099181	A1	20040527	US 2003-362140	20031031

PRIORITY APPLN. INFO.:
JP 2001-189982 A 20010622
JP 2001-190214 A 20010622
JP 2001-190215 A 20010622
JP 2001-190216 A 20010622
WO 2002-JP6248 W 20020621

OTHER SOURCE(S): MARPAT 138:74847

IT **480428-37-3**
RL: TEM (Technical or engineered material use); USES (Uses)
(phthalocyanine colorants for toners with excellent color hue and fastness)

RN 480428-37-3 HCAPLUS
CN Cuprate(4-), [[2,2',2'',2'''-[(29H,31H-phthalocyanine-2,9,16,23-tetrayl-κN29,κN30,κN31,κN32)tetrakis(sulfonylimino)]tetrakis[4-methyl-5-[[[3-[[(1-methylethyl)amino]sulfonyl]phenyl]amino]carbonyl]-3-thiophenecarboxylato]](6-)]-, tetrahydrogen, (SP-4-1)- (9CI) (CA INDEX NAME)

PAGE 1-B



L8 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B



L8 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-C



PAGE 3-B



L8 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 3-C

PAGE 4-A

●4 H+

PAGE 4-B



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Apr 2002
GI



AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

ACCESSION NUMBER: 2002:275753 HCAPLUS
DOCUMENT NUMBER: 136:309843
TITLE: Preparation of thiophenes as phosphate transport inhibitors
INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028353	A2	20020411	WO 2001-US31318	20011005
WO 2002028353	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002013048	A5	20020415	AU 2002-13048	20011005

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PRIORITY APPLN. INFO.: US 2000-238068P P 20001005
WO 2001-US31318 W 20011005

OTHER SOURCE(S): MARPAT 136:309843

IT 409361-90-6P 409361-91-7P 409361-92-8P
409361-93-9P 409361-94-0P 409361-99-5P
409362-00-1P 409362-01-2P 409362-02-3P
409362-03-4P 409362-04-5P 409362-05-6P
409362-06-7P 409362-11-4P 409362-12-5P
409362-13-6P 409362-14-7P 409362-17-0P
409362-18-1P 409362-19-2P 409362-20-5P
409362-22-7P 409362-28-3P 409362-29-4P
409362-30-7P 409362-31-8P 409362-32-9P
409362-33-0P 409362-34-1P 409362-35-2P
409362-36-3P 409362-37-4P 409362-38-5P
409362-39-6P 409362-40-9P 409362-41-0P
409362-42-1P 409362-43-2P 409362-44-3P
409362-45-4P 409362-46-5P 409362-47-6P
409362-48-7P 409362-49-8P 409362-50-1P
409362-51-2P 409362-52-3P 409362-53-4P
409362-54-5P 409362-55-6P 409362-56-7P
409362-57-8P 409362-58-9P 409362-59-0P
409362-60-3P 409362-61-4P 409362-62-5P
409362-63-6P 409362-64-7P 409362-65-8P
409362-66-9P 409362-67-0P 409362-68-1P
409362-69-2P 409362-70-5P 409362-71-6P
409362-72-7P 409362-73-8P 409362-75-0P
409362-76-1P 409362-77-2P 409362-78-3P
409362-81-8P 409362-82-9P 409362-83-0P
409362-84-1P 409362-85-2P 409362-87-4P
409362-93-2P 409362-95-4P 409362-97-6P
409362-98-7P 409363-00-4P 409363-01-5P
409363-02-6P 409363-03-7P 409363-04-8P
409363-05-9P 409363-06-0P 409363-07-1P
409363-08-2P 409363-10-6P 409363-15-1P
409363-17-3P 409363-19-5P 409363-21-9P
409363-25-3P 409363-27-5P 409363-28-6P
409363-29-7P 409363-30-0P 409363-31-1P
409363-32-2P 409363-35-5P 409363-36-6P
409363-41-3P 409363-51-5P 409363-52-6P
409363-53-7P 409363-54-8P 409363-57-1P
409363-58-2P 409363-59-3P 409363-60-6P
409363-61-7P 409363-62-8P 409363-63-9P
409363-64-0P 409363-65-1P 409363-66-2P
409363-67-3P 409363-69-5P 409363-70-8P
409363-71-9P 409363-72-0P 409363-73-1P
409363-74-2P 409363-75-3P 409363-76-4P
409363-77-5P 409363-78-6P 409363-79-7P
409363-80-0P 409363-81-1P 409363-82-2P
409363-83-3P 409363-84-4P 409363-85-5P
409363-86-6P 409363-87-7P 409363-88-8P
409363-89-9P 409363-90-2P 409363-91-3P
409363-92-4P 409363-93-5P 409363-94-6P
409363-95-7P 409363-96-8P 409363-97-9P
409363-98-0P 409363-99-1P 409364-00-7P
409364-01-8P 409364-02-9P 409364-03-0P
409364-04-1P 409364-05-2P 409364-06-3P
409364-29-0P 409364-31-4P 409364-33-6P
409364-35-8P 409364-37-0P 409364-39-2P
409364-41-6P 409364-43-8P 409364-45-0P
409364-47-2P 409364-49-4P 409364-51-8P
409364-53-0P 409364-54-1P 409364-56-3P
409364-64-3P 409364-65-4P 409364-66-5P

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
409364-67-6P 409364-68-7P 409364-69-8P
409364-70-1P 409364-71-2P 409364-72-3P
409364-73-4P 409364-81-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiophenes as phosphate transport inhibitors)

RN 409361-90-6 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3-chlorophenyl)-4-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409361-91-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409361-92-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409361-93-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409361-94-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409361-99-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-00-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-01-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-02-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-03-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-04-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-05-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-06-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-11-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-12-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-18-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-19-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 409362-20-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-13-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-14-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-17-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(trifluoromethyl)phenyl]-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-22-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-28-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-29-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-methylethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409362-30-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-phenoxyphenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-31-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(hexyloxy)phenyl]-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-32-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-methoxyphenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-33-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-methylethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-37-4 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)



RN 409362-38-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-oxopropyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-39-6 HCAPLUS
CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-34-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-acetylphenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-35-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-benzoylphenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409362-36-3 HCAPLUS
CN Benzeneacetic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 409362-40-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(2-hydroxyethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-41-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-42-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(diethylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-43-2 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 409362-44-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 409362-45-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[(1H-indazol-6-ylamino)sulfonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-46-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409362-47-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(hydroxymethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-52-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-phenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-53-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409362-54-5 HCAPLUS
CN Benzoic acid, 2-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-48-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-cyclohexylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-49-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-50-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-51-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409362-55-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-56-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,6-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-57-8 HCAPLUS
CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409362-58-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-59-0 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, N-1,3-benzodioxol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-60-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-61-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-62-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-benzoyl-4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-63-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(1H-indol-2-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-64-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-5-isoquinolinyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-65-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-2-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-66-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-9H-fluoren-2-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-67-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[(phenylamino)carbonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-68-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-69-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-2-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-70-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-71-6 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 409362-72-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-73-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-75-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409362-76-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-acetylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-77-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-84-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(1H-pyrrol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-85-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-87-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-93-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-ethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409362-78-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 409362-81-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-82-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409362-83-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409362-95-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-97-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-98-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-00-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-01-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-benzotriazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-02-6 HCAPLUS
CN Benzoic acid, 2-methoxy-5-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-03-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methyl-6-benzothiazolyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-04-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(1,3-dihydro-5-isobenzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-05-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-06-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(2-methyl-4-pyrimidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-07-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(5-oxazolyl)phenyl]-3-[(phenylsulfonyl)amino]-

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 409363-08-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-5-quinolinyl- (9CI) (CA INDEX NAME)



RN 409363-10-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-15-1 HCAPLUS
CN Benzoic acid, 4-methoxy-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-17-3 HCAPLUS
CN Benzoic acid, 4-methyl-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-19-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(phenylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-21-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-25-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 409363-27-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-28-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-35-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409363-36-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409363-41-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-51-5 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409363-29-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-30-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(dimethylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-31-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-32-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, N-[2-(phenylmethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-52-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-3-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-53-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(4-chlorophenoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-54-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(methylthio)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-57-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-1-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)



RN 409363-58-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-59-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-60-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-5-benzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-61-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chloro-3-methylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-62-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409363-63-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-64-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-65-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(3-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-66-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-67-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-69-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-70-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-71-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-72-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409363-73-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chloro-3,5-dimethylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-74-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-bromophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-75-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-76-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-77-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-78-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(5-fluoro-2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-79-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-80-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-2-methylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-81-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-82-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-83-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-84-4 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, 3-[[(2-bromophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-85-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,6-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-86-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-iodophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 409363-87-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-88-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-89-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-acetylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-90-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chloro-4-cyanophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-91-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-cyanophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-92-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-93-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-dichloro-4-hydroxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-94-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,5-dimethoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409363-98-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-99-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,5-dimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-00-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 409363-95-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-96-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-methoxy-5-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-97-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluoro-4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-01-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-02-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-ethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-03-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,4,6-trimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-04-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(2-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-05-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(1-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-06-3 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-33-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-35-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-37-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-29-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 409364-31-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-39-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(hexyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-41-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-43-8 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-45-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-47-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-53-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 409364-54-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-56-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-49-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-51-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-64-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-5-(4-fluorophenyl)-3-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-65-4 HCAPLUS
CN [2,2'-Bithiophene]-5-carboxamide, N-(3-chlorophenyl)-4-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-66-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-chlorophenyl)sulfonyl]amino]-4-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-67-6 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409364-68-7 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3,5-difluorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409364-69-8 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409364-70-1 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-fluorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409364-71-2 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3-fluorophenyl)-4-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409364-72-3 HCAPLUS

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 3-Thiophenecarboxamide, 4-[[(3,4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 409364-73-4 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-2-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409364-81-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 23 Jan 2000
GI



I II

AB The title compds. [I; A1 = (un)substituted phenylene, naphthylene, heteroarylene; ring A2 comprises the carbon atoms which carry the groups C(:X)NH and NHSO2R2 is a benzene, naphthalene, (un)saturated 3-7 membered carbocycle, etc.; R1 = (un)substituted aryl, heterocyclyl, C1-18 alkyl; R2 = (un)substituted aryl, heterocyclyl, C1-10 alkyl, etc.; R3 = H, halo, CF3, etc.; n = 0-2; X = O, NH], useful for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis, were prepared The compds. I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. Thus, reacting 4-([2-(4-chlorophenylsulfonyl)-4,5-dimethoxybenzoyl]amino)benzenesulfonyl fluoride (preparation given) with thiomorpholine afforded 65% II which showed 34.8-fold stimulation ([cGMP]test substance/[cGMP]control) at 50 μM.

ACCESSION NUMBER: 2000:53572 HCAPLUS
DOCUMENT NUMBER: 132:93104
TITLE: Preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production
INVENTOR(S): Schindler, Ursula; Schonafinger, Karl; Strobel, Hartmut
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002851	A1	20000120	WO 1999-EP4426	19990625

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW

L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19830430	A1	20000113	DE 1998-19830430		19980708
DE 19903126	A1	20000803	DE 1999-19903126		19990127
CA 2336807	AA	20000120	CA 1999-2336807		19990625
AU 9946160	A1	20000201	AU 1999-46160		19990625
AU 761983	B2	20030612			
BR 9911914	A	20010327	BR 1999-11914		19990625
EP 1095016	A1	20010502	EP 1999-929318		19990625
EP 1095016	B1	20051109			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
JP 2002520309	T2	20020709	JP 2000-559082		19990625
RU 2234497	C2	20040820	RU 2001-103645		19990625
AT 309206	E	20051115	AT 1999-929318		19990625
NO 2001000013	A	20010301	NO 2001-13		20010102
PRIORITY APPLN. INFO.:			DE 1998-19830430	A	19980708
			DE 1999-19903126	A	19990127
			WO 1999-EP4426	W	19990625

OTHER SOURCE(S): MARPAT 132:93104

IT **254877-23-1P 254877-27-5P 254878-40-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production)

RN 254877-23-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254877-27-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 254878-40-5 HCAPLUS

CN Benzenesulfonyl fluoride, 4-[[[3-[[(4-chlorophenyl)sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 13 Jan 2000

GI



I

AB Title compds. [I; A1 = (substituted) phenylene, naphthylene, heteroarylene; A2 = atoms to form Ph, naphthyl, carbocyclyl, heterocyclyl rings; R1 = (substituted) aryl, heterocyclyl, alkyl; R2 = R1, amino; R3 = ≥1 of H, halo, CF3, OH, alkoxy, alkoxyalkoxy, aryloxy, NO2, cyano, amino, CO2H, etc.; X = O, NH, etc.; n = 0-2], were prepared Thus, 4-[[2-(4-chlorphenylsulfonylamino)-4,5-dimethoxybenzoyl]amino]benzenesulfonyl fluoride was heated in thiomorpholine at 90° for 30 min. to give 65% 2-(4-chlorophenylsulfonylamino)-4,5-dimethoxy-N-[4-(thiomorpholin-4-sulfonyl)phenyl]benzamide. The latter at 50 μM gave 34.8-fold stimulation of soluble guanylate cyclase.

ACCESSION NUMBER: 2000:31524 HCAPLUS

DOCUMENT NUMBER: 132:93102

TITLE: Preparation of arylsulfonylaminoarylamides as guanylate cyclase activators.

INVENTOR(S): Schindler, Ursula; Schoenafinger, Karl; Strobel, Hartmut

PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany

SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19830430	A1	20000113	DE 1998-19830430	19980708
CA 2336807	AA	20000120	CA 1999-2336807	19990625
WO 2000002851	A1	20000120	WO 1999-EP4426	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9946160	A1	20000201	AU 1999-46160	19990625
AU 761983	B2	20030612		
BR 9911914	A	20010327	BR 1999-11914	19990625
EP 1095016	A1	20010502	EP 1999-929318	19990625
EP 1095016	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
TR 200100147	T2	20010521	TR 2001-200100147	19990625
JP 2002520309	T2	20020709	JP 2000-559082	19990625
RU 2234497	C2	20040820	RU 2001-103645	19990625
AT 309206	E	20051115	AT 1999-929318	19990625
US 6335334	B1	20020101	US 1999-349933	19990708
ZA 2000007486	A	20020104	ZA 2000-7486	20001214

L8 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

NO 2001000013	A	20010301	NO 2001-13		20010102
US 2002061887	A1	20020523	US 2001-994730		20011128
US 6881735	B2	20050419			
US 2004186145	A1	20040923	US 2004-816143		20040402
PRIORITY APPLN. INFO.:			DE 1998-19830430	A	19980708
			DE 1999-19903126	A	19990127
			WO 1999-EP4426	W	19990625
			US 1999-349933	A3	19990708
			US 2001-994730	A3	20011128

OTHER SOURCE(S): MARPAT 132:93102

IT **254877-23-1P 254877-27-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylsulfonylaminoarylamides as guanylate cyclase activators)

RN 254877-23-1 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254877-27-5 HCAPLUS

CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



IT **254878-40-5P**

L8 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arylsulfonylaminoarylamides as guanylate cyclase activators)
RN 254878-40-5 HCAPLUS
CN Benzenesulfonyl fluoride, 4-[[[3-[[(4-chlorophenyl)sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 03 Aug 1998
GI



AB The title compds. [I; XA = N-containing heterocyclyl; Y = CONH, (CH2)m, etc.; m = 2, 3; n = 0, 1; Z = 1,4-Ph, N-containing heterocyclyl] are prepared I are useful as fibrinogen receptor antagonists and inhibitors of the aggregation of blood platelets in a mammal (no data). Thus, compound (II; W = BOC, Q = Me) (preparation given) was treated with 1N NaOH and then treated with TFA to give the title compound II (W = Q = H).
ACCESSION NUMBER: 1998:479027 HCAPLUS
DOCUMENT NUMBER: 129:122673
TITLE: Fibrinogen receptor antagonists
INVENTOR(S): Wai, John; Fisher, Thorsten E.; Duggan, Mark E.; Hartman, George D.; Perkins, James J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 37 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5780480	A	19980714	US 1997-807843	19970226
PRIORITY APPLN. INFO.:			US 1997-807843	19970226
OTHER SOURCE(S):	MARPAT 129:122673			

IT **210347-33-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzene derivs. as fibrinogen receptor antagonists)
RN 210347-33-4 HCAPLUS
CN Glycine, N-(phenylsulfonyl)-N-[5-[[[4-(1-piperazinyl)phenyl]amino]carbonyl]-2-thienyl]-, trifluoroacetate (10:17) (9CI) (CA INDEX NAME)

CM 1

CRN 196204-14-5
CMF C23 H24 N4 O5 S2

L8 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT **196204-13-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzene derivs. as fibrinogen receptor antagonists)
RN 196204-13-4 HCAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[[[5-[(2-methoxy-2-oxoethyl)(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 17 Sep 1997
GI



AB Fibrinogen receptor antagonists of the general formula X-A-Y-Z-B [X = heterocycle; A = R1a-substituted phenylene, NR1, R1a-substituted piperidinediyl; Y = alkylene or other divalent bridging group; Z = aryl, heterocycle; B = (CH2)mNR4CH(R3)COR5; R1, R3 = independently H, C1-10 alkyl, C3-8 cycloalkyl, aryl-C0-8 alkyl, amino-C0-8 alkyl, C1-6 alkylamino-C0-8 alkyl, C1-6 dialkylamino-C0-8 alkyl, C1-3 acylamino-C0-8 alkyl, C0-6 alkyl-CO2H, C0-6 alkyl-CO2C-1-3 alkyl, OC0-6 alkyl-CO2H, HOC0-6 alkyl; R1a = any group R1, halo, oxo; R2 = any group R1, halo; R4 = (CH2)p-D-R6, Q1, Q2; Z-B = heterocyclic group Q3; D = SO2, CO; R5 = OH, C1-8 alkoxy, aryl C0-5 alkyloxy, C1-8 alkylcarbonyloxy C1-4 alkoxy, aryl C1-8 alkylcarbonyloxy C1-4 alkoxy, L- or D-amino acid residue optionally esterified by C1-6 alkyl; R6 = CF3, C3-6 cycloalkyl, (un)substituted C1-6 alkyl, C0-6 alkylaryl, C0-6 alkylheterocyclyl, NR1C1-6 alkyl, NR1C0-6 alkylaryl, NR1C0-6 alkylheterocyclyl; m = 0-1; p = 0-2] and which includes, for example, compds. I, are useful for inhibiting the binding of fibrinogen to blood platelets, inhibiting the aggregation of blood platelets, treating thrombus formation or embolus formation, and preventing thrombus or embolus formation. Thus, sequential reaction of 4-O2NC6H4NH2 with PhSO2Cl and BrCH2CO2Et gave N-aryl-N-sulfonylglycine ester 4-O2NC6H4N(SO2Ph)CH2CO2Et (II). Catalytic reduction of II, followed by amidation with 4-(4-tert-butoxycarbonylpiperazin-1-yl)benzoyl chloride and deprotection gave desired antagonist I (Y = CONH, D = SO2, R1 = R1a = R2 = R3 = H; R5 = OH, R6 = Ph).
ACCESSION NUMBER: 1997:594724 HCAPLUS
DOCUMENT NUMBER: 127:263057
TITLE: Preparation of heterocyclic fibrinogen receptor antagonists
INVENTOR(S): Wai, John; Duggan, Mark E.; Fisher, Thorsten E.; Hartman, George D.; Perkins, James J.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Wai, John; Duggan, Mark E.; Fisher, Thorsten E.; Hartman, George D.; Perkins, James J.
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

L8 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9731910	A1	19970904	WO 1997-US2712	19970224
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2246756	AA	19970904	CA 1997-2246756	19970224
AU 9721332	A1	19970916	AU 1997-21332	19970224
AU 712082	B2	19991028		
EP 885205	A1	19981223	EP 1997-906712	19970224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000505471	T2	20000509	JP 1997-531013	19970224

PRIORITY APPLN. INFO.: US 1996-12380P P 19960228
GB 1996-6489 A 19960327
WO 1997-US2712 W 19970224

OTHER SOURCE(S): MARPAT 127:263057

IT **196204-14-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic fibrinogen receptor antagonists)

RN 196204-14-5 HCAPLUS

CN Glycine, N-(phenylsulfonyl)-N-[5-[[[4-(1-piperazinyl)phenyl]amino]carbonyl]-2-thienyl]- (9CI) (CA INDEX NAME)



IT **196204-13-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic fibrinogen receptor antagonists)

RN 196204-13-4 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[5-[(2-methoxy-2-oxoethyl)(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L8 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 409364-73-4 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-2-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-81-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



L8 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 23 Jan 2000
GI

AB The title compds. [I; A1 = (un)substituted phenylene, naphthylene, heteroarylene; ring A2 comprises the carbon atoms which carry the groups C(:X)NH and NHSO2R2 is a benzene, naphthalene, (un)saturated 3-7 membered carbocycle, etc.; R1 = (un)substituted aryl, heterocyclyl, C1-18 alkyl; R2 = (un)substituted aryl, heterocyclyl, C1-10 alkyl, etc.; R3 = H, halo, CF3, etc.; n = 0-2; X = O, NH], useful for the therapy and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis, were prepared The compds. I are capable of modulating the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. Thus, reacting 4-{[2-(4-chlorophenylsulfonyl)-4,5-dimethoxybenzoyl]amino}benzenesulfonyl fluoride (preparation given) with thiomorpholine afforded 65% II which showed 34.8-fold stimulation ([cGMP]test substance/[cGMP]control) at 50 μM.

ACCESSION NUMBER: 2000:53572 HCAPLUS
DOCUMENT NUMBER: 132:93104
TITLE: Preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production
INVENTOR(S): Schindler, Ursula; Schonafinger, Karl; Strobel, Hartmut
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000002851	A1	20000120	WO 1999-EP4426	19990625
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19830430	A1	20000113	DE 1998-19830430	19980708
DE 19903126	A1	20000803	DE 1999-19903126	19990127
CA 2336807	AA	20000120	CA 1999-2336807	19990625
AU 9946160	A1	20000201	AU 1999-46160	19990625
AU 761983	B2	20030612		
BR 9911914	A	20010327	BR 1999-11914	19990625
EP 1095016	A1	20010502	EP 1999-929318	19990625
EP 1095016	B1	20051109		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002520309	T2	20020709	JP 2000-559082	19990625
RU 2234497	C2	20040820	RU 2001-103645	19990625
AT 309206	E	20051115	AT 1999-929318	19990625
NO 2001000013	A	20010301	NO 2001-13	20010102

PRIORITY APPLN. INFO.:
DE 1998-19830430 A 19980708
DE 1999-19903126 A 19990127
WO 1999-EP4426 W 19990625

OTHER SOURCE(S): MARPAT 132:93104

IT **254877-23-1P 254877-27-5P 254878-40-5P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfur substituted sulfonylaminocarboxylic acid N-arylamides as modulators of cyclic guanosine monophosphate (cGMP) production)

RN 254877-23-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-morpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254877-27-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chlorophenyl)sulfonyl]amino]-N-[4-(4-thiomorpholinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)



RN 254878-40-5 HCAPLUS
CN Benzenesulfonyl fluoride, 4-[[[3-[[(4-chlorophenyl)sulfonyl]amino]-2-thienyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


O
S
F
O
O
S
C
NH
NH
O
S
O
Cl

L8 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Apr 2002
GI



I



II



III

AB The title compds. [I-III; X = S, O; R1 = H, alkyl, aryl, etc.; R2, R3 = alkyl, haloalkyl, alky; interrupted by one or more O or S atoms, etc.; n = 0-3], useful for treatment of chronic renal failure and uremic bone disease, were prepared E.g., a 4-step synthesis of I [X = S; R1 = H; R2 = 4-FC6H4; R3 = Ph], starting with Me 3-aminothiophene-2-carboxylate, was presented. Biol. data were given.

ACCESSION NUMBER: 2002:275753 HCAPLUS
DOCUMENT NUMBER: 136:309843
TITLE: Preparation of thiophenes as phosphate transport inhibitors
INVENTOR(S): Weinstock, Joseph; Franz, Robert G.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028353	A2	20020411	WO 2001-US31318	20011005
WO 2002028353	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002013048	A5	20020415	AU 2002-13048		20011005
PRIORITY APPLN. INFO.:			US 2000-238068P	P	20001005
			WO 2001-US31318	W	20011005

OTHER SOURCE(S): MARPAT 136:309843

IT **409361-90-6P 409361-91-7P 409361-92-8P**
409361-93-9P 409361-94-0P 409361-99-5P
409362-00-1P 409362-01-2P 409362-02-3P
409362-03-4P 409362-04-5P 409362-05-6P
409362-06-7P 409362-11-4P 409362-12-5P
409362-13-6P 409362-14-7P 409362-17-0P
409362-18-1P 409362-19-2P 409362-20-5P
409362-22-7P 409362-28-3P 409362-29-4P
409362-30-7P 409362-31-8P 409362-32-9P
409362-33-0P 409362-34-1P 409362-35-2P
409362-36-3P 409362-37-4P 409362-38-5P
409362-39-6P 409362-40-9P 409362-41-0P
409362-42-1P 409362-43-2P 409362-44-3P
409362-45-4P 409362-46-5P 409362-47-6P
409362-48-7P 409362-49-8P 409362-50-1P
409362-51-2P 409362-52-3P 409362-53-4P
409362-54-5P 409362-55-6P 409362-56-7P
409362-57-8P 409362-58-9P 409362-59-0P
409362-60-3P 409362-61-4P 409362-62-5P
409362-63-6P 409362-64-7P 409362-65-8P
409362-66-9P 409362-67-0P 409362-68-1P
409362-69-2P 409362-70-5P 409362-71-6P
409362-72-7P 409362-73-8P 409362-75-0P
409362-76-1P 409362-77-2P 409362-78-3P
409362-81-8P 409362-82-9P 409362-83-0P
409362-84-1P 409362-85-2P 409362-87-4P
409362-93-2P 409362-95-4P 409362-97-6P
409362-98-7P 409363-00-4P 409363-01-5P
409363-02-6P 409363-03-7P 409363-04-8P
409363-05-9P 409363-06-0P 409363-07-1P
409363-08-2P 409363-10-6P 409363-15-1P
409363-17-3P 409363-19-5P 409363-21-9P
409363-25-3P 409363-27-5P 409363-28-6P
409363-29-7P 409363-30-0P 409363-31-1P
409363-32-2P 409363-35-5P 409363-36-6P
409363-41-3P 409363-51-5P 409363-52-6P
409363-53-7P 409363-54-8P 409363-57-1P
409363-58-2P 409363-59-3P 409363-60-6P
409363-61-7P 409363-62-8P 409363-63-9P
409363-64-0P 409363-65-1P 409363-66-2P
409363-67-3P 409363-69-5P 409363-70-8P
409363-71-9P 409363-72-0P 409363-73-1P
409363-74-2P 409363-75-3P 409363-76-4P
409363-77-5P 409363-78-6P 409363-79-7P
409363-80-0P 409363-81-1P 409363-82-2P
409363-83-3P 409363-84-4P 409363-85-5P
409363-86-6P 409363-87-7P 409363-88-8P
409363-89-9P 409363-90-2P 409363-91-3P
409363-92-4P 409363-93-5P 409363-94-6P
409363-95-7P 409363-96-8P 409363-97-9P
409363-98-0P 409363-99-1P 409364-00-7P
409364-01-8P 409364-02-9P 409364-03-0P
409364-04-1P 409364-05-2P 409364-06-3P
409364-29-0P 409364-31-4P 409364-33-6P
409364-35-8P 409364-37-0P 409364-39-2P

409364-41-6P 409364-43-8P 409364-45-0P
409364-47-2P 409364-49-4P 409364-51-8P
409364-53-0P 409364-54-1P 409364-56-3P
409364-64-3P 409364-65-4P 409364-66-5P
409364-67-6P 409364-68-7P 409364-69-8P
409364-70-1P 409364-71-2P 409364-72-3P
409364-73-4P 409364-81-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiophenes as phosphate transport inhibitors)

RN 409361-90-6 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3-chlorophenyl)-4-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409361-91-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409361-92-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409361-93-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409361-94-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409361-99-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-00-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-01-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-02-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(2-

fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-03-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-04-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-05-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-4-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-06-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-11-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-12-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-13-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-14-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chloro-4-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-17-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(trifluoromethyl)phenyl]-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409362-18-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-fluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-19-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 409362-20-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-methoxyphenyl)sulfonyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-22-7 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-28-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-29-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-methylethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-30-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-phenoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-31-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(hexyloxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-32-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-33-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-methylethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-34-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-acetylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-35-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-benzoylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-36-3 HCAPLUS
CN Benzeneacetic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 409362-37-4 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, butyl ester (9CI) (CA INDEX NAME)



RN 409362-38-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(1-oxopropyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-39-6 HCAPLUS
CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 409362-40-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(2-hydroxyethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-41-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(6-methyl-2-benzothiazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-42-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(diethylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-43-2 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 409362-44-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 409362-45-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[(1H-indazol-6-ylamino)sulfonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-46-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-thiazolylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409362-47-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(hydroxymethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-48-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-cyclohexylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-49-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-50-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-51-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-52-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-phenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-53-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409362-54-5 HCAPLUS
CN Benzoic acid, 2-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 409362-55-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-56-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,6-difluorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-57-8 HCAPLUS
CN Benzoic acid, 3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-,
methyl ester (9CI) (CA INDEX NAME)



RN 409362-58-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-59-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-1,3-benzodioxol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-60-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-61-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-62-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-benzoyl-4-chlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-63-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(1H-indol-2-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-64-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-5-isoquinolinyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-65-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-2-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-66-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-9H-fluoren-2-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-67-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-[(phenylamino)carbonyl]phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-68-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-69-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-2-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-70-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-71-6 HCAPLUS
CN Benzoic acid, 4-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 409362-72-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,6-dimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-73-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-75-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-5-
oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409362-76-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-acetylphenyl)-3-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409362-77-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-78-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 409362-81-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(phenylmethoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-82-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409362-83-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-84-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[2-(1H-pyrrol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 409362-85-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-87-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-fluorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-93-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-ethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-95-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-97-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dimethylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409362-98-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dimethoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-00-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-01-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-benzotriazol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-02-6 HCAPLUS
CN Benzoic acid, 2-methoxy-5-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-03-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methyl-6-benzothiazolyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-04-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(1,3-dihydro-5-isobenzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-05-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-06-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(2-methyl-4-pyrimidinyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-07-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[3-(5-oxazolyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-08-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-5-quinolinyl- (9CI) (CA INDEX NAME)



RN 409363-10-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chlorophenyl)-3-[(phenylsulfonyl)amino]-(9CI) (CA INDEX NAME)



RN 409363-15-1 HCAPLUS
CN Benzoic acid, 4-methoxy-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-17-3 HCAPLUS
CN Benzoic acid, 4-methyl-3-[[[3-[(phenylsulfonyl)amino]-2-thienyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 409363-19-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(phenylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-21-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 409363-25-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(2,4,6-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 409363-27-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1H-inden-5-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-28-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-29-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-1H-indol-5-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-30-0 HCAPLUS

CN 2-Thiophenecarboxamide, N-[4-(dimethylamino)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-31-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methoxyphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-32-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-methylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-35-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[4-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 409363-36-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409363-41-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-dichlorophenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-51-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(phenylmethyl)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-52-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-[1,1'-biphenyl]-3-yl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-53-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-[4-(4-chlorophenoxy)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-54-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-[2-(methylthio)phenyl]-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-57-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-1-naphthalenyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-58-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-difluorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-59-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-4-methyl-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-60-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dihydro-5-benzofuranyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-61-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2-chloro-3-methylphenyl)-3-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409363-62-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[(phenylsulfonyl)amino]-N-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 409363-63-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[3-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-64-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-65-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(3-chlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-66-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3-

fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-67-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-69-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-fluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-70-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-71-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-72-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-73-1 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-chloro-3,5-dimethylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-74-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-bromophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-75-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-76-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-77-5 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-78-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(5-fluoro-2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-79-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-80-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3-chloro-2-methylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-81-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-82-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-83-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chloro-4-fluorophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-84-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-bromophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-85-5 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,6-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-86-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-iodophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-87-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,4-dichlorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-88-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-nitrophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-89-9 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(4-acetylphenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-90-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(2-chloro-4-cyanophenyl)sulfonyl]amino]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 409363-91-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-cyanophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-92-4 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-93-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-dichloro-4-hydroxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-94-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,5-dimethoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-95-7 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-96-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-methoxy-5-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-97-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(3,5-difluoro-4-methoxyphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-98-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409363-99-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,5-dimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-00-7 HCAPLUS

CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-01-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-02-9 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-ethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-03-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(2,4,6-trimethylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-04-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(2-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-05-2 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[(1-naphthalenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-06-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-29-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 409364-31-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 409364-33-6 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-35-8 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-37-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,5-difluorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-39-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(hexyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-41-6 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-butoxyphenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-43-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(4-chlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-45-0 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3,4-dichlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-47-2 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-49-4 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-51-8 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-benzoylphenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-53-0 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 409364-54-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-3-[[(3,4-difluorophenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-56-3 HCAPLUS
CN 2-Thiophenecarboxamide, 3-[[(3,4-difluorophenyl)sulfonyl]amino]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 409364-64-3 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-5-(4-fluorophenyl)-3-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-65-4 HCAPLUS
CN [2,2'-Bithiophene]-5-carboxamide, N-(3-chlorophenyl)-4-[[(2-methylphenyl)sulfonyl]amino]- (9CI) (CA INDEX NAME)



RN 409364-66-5 HCAPLUS
CN 2-Thiophenecarboxamide, N-(3-chlorophenyl)-3-[[(4-chlorophenyl)sulfonyl]amino]-4-methyl- (9CI) (CA INDEX NAME)



RN 409364-67-6 HCAPLUS

CN 3-Thiophenecarboxamide, N-(4-chlorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409364-68-7 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3,5-difluorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409364-69-8 HCAPLUS
CN 3-Thiophenecarboxamide, N-(2,3-dichlorophenyl)-4-[(phenylsulfonyl)amino]-
(9CI) (CA INDEX NAME)



RN 409364-70-1 HCAPLUS
CN 3-Thiophenecarboxamide, N-(4-fluorophenyl)-4-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-71-2 HCAPLUS
CN 3-Thiophenecarboxamide, N-(3-fluorophenyl)-4-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)



RN 409364-72-3 HCAPLUS
CN 3-Thiophenecarboxamide, 4-[[(3,4-difluorophenyl)sulfonyl]amino]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)





I



II